Become Affiliate

PepFlow

Download

The GH Standard

Somatropin

Somatropin is recombinant human growth hormone, a 191-amino-acid pituitary hormone manufactured as prescription injectable products.

GH therapyMuscle repairRecovery support
TierS
EvidenceStrong
SafetyWell-Studied
FDA statusApproved
Last reviewed October 25, 2026 50 citations How to read these labels

What is Somatropin?

Somatropin is recombinant human growth hormone, a 191-amino-acid pituitary hormone manufactured as prescription injectable products.[1][2][3]

It has FDA-approved indications such as growth hormone deficiency and selected pediatric growth or wasting contexts, depending on product label.[1][2][3]

That approved-drug evidence does not generalize to anti-aging, bodybuilding, recovery, or performance protocols, which carry different benefit-risk and anti-doping issues.[1][2][3] For more context, read the recombinant human growth hormone explainer.

What Somatropin is investigated for

Somatropin evidence is grouped by practical use case and injectable, intranasal, inhaled, oral, transdermal, and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Pediatric growth hormone deficiency and short-stature disorders

Injectable

90%Strong

Pediatric growth-disorder treatment has high-confidence, clinician-managed evidence.[3][1][5][7]

Human evidence

FDA labeling and pediatric endocrine guidelines support somatropin for pediatric growth hormone deficiency and selected short-stature disorders.[3][1][5][7]

Animal / mechanistic evidence

The mechanism is GH receptor and IGF-1 axis replacement in true deficiency or approved pediatric growth-disorder contexts.[3][1][5][7]

Adult growth hormone deficiency

Injectable

82%Strong

Adult GH deficiency should be its own high-confidence indication rather than hidden inside pediatric growth claims.[3][10][12][14]

Human evidence

FDA labeling and adult GH deficiency literature support replacement therapy for diagnosed adult GH deficiency.[3][10][12][14]

Animal / mechanistic evidence

The rationale is physiologic replacement and IGF-1 monitoring, not supraphysiologic enhancement.[3][10][12][14]

Lean mass, fat loss, aging, and performance use in healthy adults

Injectable

56%Emerging

Lean-mass, fat-loss, and anti-aging claims remain lower confidence and clearly off-label for healthy adults.[12][14][3][20]

Human evidence

Adult GH studies show fat-mass and lean-mass effects in deficiency contexts, but healthy-adult anti-aging and performance use is not an approved indication.[12][14][3][20]

Animal / mechanistic evidence

The mechanism is anabolic and lipolytic GH/IGF-1 signaling, which also explains adverse-effect and anti-doping concerns.[12][14][3][20]

Evidence snapshot

90%

Human evidence

Strong

FDA-approved somatropin products have labeled endocrine indications with dose and safety monitoring.[1][2][3]

34%

Animal / preclinical

Limited

GH receptor and IGF-1 biology directly supports replacement therapy.[1][2][3]

90%

Mechanism support

Strong

Somatropin binds growth hormone receptors and increases hepatic and local IGF-1 signaling. The axis affects growth, body composition, glucose, fluid balance, and tissue turnover.[1][2][3]

Forms & administration

Somatropin is supplied as approved injectable medicines, including ready-to-use Norditropin FlexPro pens. Nasal, inhaled and local dental formulations remain investigational. Encapsulated oral and microneedle preparations have preclinical support only; their amounts, absorption and preparation cannot be equated with prescription injectable products.[3][18][1][21][22][23][24][25]

InjectableNasal sprayInhaledOralTransdermalTopical

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Adult growth hormone deficiency usually starts at 0.15-0.30 mg per day. A common starting dose is 0.2 mg.[27]

Frequency

Usually taken once daily.[27]

Timing Considerations

Evening is the usual timing.[27]

Cycle Length

Treatment is ongoing and adjusted over time.[27]

What to expect

First weeks

Injectable somatropin replacement may feel like shifts in energy, sleep, body-fluid balance, or adult GH-deficiency symptoms.[1][2][3][18]

Months

Injectable treatment outcomes unfold through pediatric growth velocity or adult body composition, symptoms, IGF-1, and metabolic labs.[1][2][3][18]

After stopping

Hormone-axis effects drift toward baseline after injectable somatropin stops unless the underlying deficiency is treated another way.[1][2][3][18]

Safety profile

Somatropin has prescription-label safety concerns around glucose, fluid retention, joint symptoms, malignancy, intracranial pressure, retinopathy, and pediatric indication limits.[3][1][2]

Common side effects

Cautions

What we don't know

Anti-aging, bodybuilding, and other non-replacement uses have a different risk-benefit profile from approved somatropin therapy.[3][1][2]

Who Somatropin is not for

Route-specific avoid and medical-review notes:

  • Active malignancy

    Active malignancy warrants medical review or avoidance for Somatropin.[3][1][2]

  • Acute critical illness per label

    Acute critical illness per label use warrants medical review or avoidance for Somatropin.[3][1][2]

  • Pregnancy or breastfeeding without clinician review

    Pregnancy or breastfeeding without clinician review warrants medical review or avoidance for Somatropin.[3][1][2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Documented interactions

  • Glucocorticoids

    The Norditropin label states somatropin can reduce cortisol concentrations and glucocorticoid replacement doses may require adjustment.[3][1][2]

  • CYP450-metabolized drugs

    The Norditropin label says somatropin may alter clearance of drugs metabolized by CP450 liver enzymes.[3][1][2]

  • Oral estrogen

    The Norditropin label states oral estrogens may reduce IGF-1 response and higher somatropin doses may be required.[3][1][2]

  • Insulin / hypoglycemic agents

    The Norditropin label states somatropin may decrease insulin sensitivity and diabetes medications may require dose adjustment.[3][1][2]

Theoretical interactions

  • GH secretagogues

    Ipamorelin, GHRPs, sermorelin, or IGF products can stack GH/IGF exposure, edema, and glucose effects; this is a GH/insulin-axis caution.[3][1][2]

  • Anabolic hormones

    Testosterone or anabolic agents can compound edema, sleep-apnea, and growth-signal tracking; this is a theoretical pathway caution.[3][1][2]

Pairing notes

Not recommended with

Tesamorelin: compounded GH/IGF-1 effectsInjectable

Somatropin supplies growth hormone directly, while tesamorelin increases the body's own growth-hormone release. Using both can compound GH/IGF-1, fluid-retention, and glucose effects.[3]

CJC-1295: added GH-axis stimulationInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[40][41][3]

CJC-1295 No DAC: added GH-axis stimulationInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[42][31][3]

Sermorelin: added GH-axis stimulationInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[43][44][3]

Ipamorelin: added GH-axis stimulationInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[45][46][3]

GHRP-2: added GH-axis stimulationInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[47][48][3]

GHRP-6: added GH-axis stimulationInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[49][48][3]

Hexarelin: added GH-axis stimulationInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[50][19][3]

How it works

Somatropin binds growth hormone receptors and increases hepatic and local IGF-1 signaling. In plain terms, it replaces or augments a hormone axis that affects linear growth, body composition, glucose handling, water retention, and tissue turnover.[1][2][3]

Injectable prescription use is inseparable from monitoring. The same GH/IGF-1 pathway explains glucose intolerance, edema, joint symptoms, intracranial-pressure symptoms, neoplasm-history review, and pediatric growth-plate status, so wellness or bodybuilding extrapolations are not route-labeled medicine. The route is medical only when paired with diagnosis and follow-up.[1][2][3]

Research gaps & open questions

What the current literature has not yet settled about Somatropin:

01

Trials in adults without growth-hormone deficiency still need to show whether anti-aging use provides meaningful benefits that outweigh risks such as swelling, joint pain, blood-sugar problems, and abnormal tissue growth.[1][2][3]

02

Long-term safety is not established for healthy or non-deficient users, especially with repeated or high-dose exposure.[1][2][3]

03

It is not clear how off-label users can be monitored safely outside endocrine care, including which symptoms or changes in IGF-1, blood sugar, and thyroid function should trigger a dose change or stop.[1][2][3]

Common questions

Is somatropin HGH?

Yes. Somatropin is recombinant human growth hormone, an injectable prescription product used for specific labeled growth hormone indications.[18][19][3][1]

Is somatropin FDA-approved?

Yes. Somatropin injection products are FDA-approved in the U.S. for specific labeled growth hormone indications.[18][19][3][1]

Is HGH approved for anti-aging?

No. HGH is not FDA-approved for anti-aging or performance use; those outcomes are separate from approved somatropin indications.[18][19][3][1]

Myths & misconceptions

Myth

HGH is just a recovery peptide.

Reality

It is a systemic hormone with glucose, fluid, cancer-history, and endocrine monitoring issues.[1][2][3]

Myth

FDA approval makes any HGH use legitimate.

Reality

Approval is indication-, product-, and route-specific.[1][2][3]

History & discovery

Somatropin replaced earlier pituitary-derived growth hormone with recombinant human growth hormone products that could be manufactured consistently. Its history is prescription endocrinology, not generic wellness. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[1][2][3]

Recombinant somatropin became established for specific pediatric and adult growth-hormone indications. That history tied dosing to diagnosis, monitoring, and product labeling.[1][2][3]

Clinical guidelines separated supported growth-hormone uses from weaker or off-label claims. Anti-aging and performance markets grew anyway, making safety and legality central to modern interpretation.[1][2][3]

Published research50 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your long-term goals.

Use PepFlow to record your Somatropin protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00